LNC Therapeutics raises €6.5m to reinforce its R&D in the microbiota field

47e64bcf-896e-4bc0-b4db-413992dc9498articleimage.jpg

29 Sep 2017 --- LNC Therapeutics, a company specialized in the research and development of gut microbiota directed drugs for the treatment of obesity and associated cardiometabolic diseases, has raised a €6.5 million (US$7.67 million) Series C funding round. This new round, co-led by Seventure Partners, brings together a consortium of investors and a family office. Additionally, the company has appointed a new chief scientific officer, Dr. Sandrine Claus, to lead the gut microbiota project.

“This funding round of €6.5 million establishes LNC Therapeutics as a key player in the treatment of obesity and metabolic disorders through an action on the gut microbiota,” explains Jean-Luc Treillou, LNC therapeutics’ CEO. 

“Our recent clinical trial on obese patients indicated that visceral fat loss in this population was correlated with a modulation of the gut microbiota, specifically with a bacterial family known for its anti-obesity potential,” Treillou adds.

“Hence, our current objective is to develop new drug candidates whose mechanism of action requires interaction with the gut microbiota and the intestinal membrane. Targeted therapeutic indications include pathologies caused by excessive visceral fat accumulation and chronic inflammation such as obesity and NASH.”

“The presentation of our development plan is scheduled in the first quarter of 2018 and will include targets and project milestones,” Caroline Bernard, Strategic Development Project Manager at LNC Therapeutics, tells NutritionInsight.

Regarding the populations LNC Therapeutics intends to target its research on, Bernard adds that LNC will indeed focus on some specific (but still large) sub-populations to maximize clinical outcomes, but did not provide further details on these sub-populations.

Click to EnlargeNew CSO
Newly appointed Chief Scientific Officer Sandrine Claus, Ph.D., is Associate Professor in Integrative Metabolism at the University of Reading, which she joined in 2010. Its research focuses on the host-gut microbial metabolic interactions to link gut microbial ecology to metabolic health.

Claus’ mission within LNC Therapeutics will be leading the ambitious R&D pipeline and the development of new treatments in the field of cardiometabolic diseases and other fields of investigation relating to the bioactivity of some peptides.

“It is with great pleasure that I am joining LNC Therapeutics and its dynamic team. It is an exciting time to join a company which owns a large pipeline of innovative patents related to gut microbiota activity, aimed at improving health outcomes,” comments Sandrine Claus.

“Our new CSO, Dr. Sandrine Claus, Ph.D., who is an expert on the role of gut microbiota in the development of metabolic disorders, is a strategic recruitment. Our strategic plan now has to be delivered and will drive us to an IPO by the end of 2019,” concludes Jean-Luc Treillou.

“We are pleased to participate in this new round and to have syndicated the Series C with other ‘deep pocket’ investors. LNC Therapeutics, a company we have supported since the Series A, chose to remain discreet over the last two years in the booming universe of the microbiome, to gain a foothold and consolidate its competitive position. LNC Therapeutics is complementing our portfolio of microbiome champions, consisting of companies that are advanced in their research,” adds Isabelle de Crémoux, CEO of Seventure Partners and founder of Health For Life Capital.

By Lucy Gunn

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Health & Nutrition News

Molecular switch may serve as new target point for obesity and diabetes therapies, says study

16 Aug 2018 --- A mechanism of the PI3KC2A kinase enzyme may have significance for the future development of therapies against cancer, obesity and diabetes, research published in Molecular Cell has found. The study highlights how if specific signaling cascades are misregulated, diseases and metabolic disorders may occur. The identified mechanism may have a crucial influence on such signaling cascades.

Health & Nutrition News

Palm tocotrienol holds potential for brain health, study suggests

10 Jul 2018 --- Supplementation with palm tocotrienol improves behavioral and cognitive abilities in transgenic – genetically modified – Alzheimer’s mice, a joint study conducted by the National University of Malaysia and Shiga University of Medical Science, Japan has found. Tocotrienol has garnered wide attention as a potential therapeutic agent against neurodegenerative disease due to its potent antioxidant and neuroprotective properties, the study explains, but this is the “first” study to evaluate the effect of tocotrienol-rich fraction (TRF) – consisting of a mixture of vitamin E analogs – of palm oil on behavior and cognitive functions in Alzheimer’s mice. 

Health & Nutrition News

Zero proof that probiotics can ease your anxiety, research reveals

21 Jun 2018 --- Those hoping to alleviate their anxiety with the use of probiotics should probably put down that yogurt spoon or supplement bottle and call a professional instead. This is according to researchers from the University of Kansas who reviewed available research, finding evidence that probiotics can reduce anxiety in rodents, but not in humans. The researchers reviewed data from 22 preclinical studies involving 743 animals and 14 clinical studies of 1,527 individuals, and found that probiotics did “not significantly reduce symptoms of anxiety in humans and did not differentially affect clinical and healthy human samples.”

Health & Nutrition News

DSM’s Nutrition Improvement focus: Fresh thinking on global nutrition and food fortification

15 Jun 2018 --- “We work with our customers and the larger malnutrition-fighting community to treat and prevent malnutrition,” Anthony Hehir, Director of DSM’s Nutrition Improvement Business Segment, tells NutritionInsight. Using its solid science and technical heritage, DSM is striving to fight global malnutrition through its “business with a purpose” approach. NutritionInsight spoke to Hehir, gaining an insight into what drives the company’s staple food fortification technologies, research and future nutrition endeavors. 

Health & Nutrition News

Gut-brain axis: Multi-strain probiotic holds potential for IBS symptom relief 

12 Jun 2018 --- A multi-strain probiotic supplement has resulted in strong symptom reductions in those suffering from Irritable Bowel Syndrome – diarrhea  (IBS-D), a study conducted at the University of Bangabandhu Sheikh Medical University in Bangladesh has found. The 14 strains of “gut-friendly” bacteria in the supplement – Bio-Kult – were also found to reduce anxiety, tapping into the growing space of gut-brain axis products.

More Articles
URL : http://www.nutritioninsight.com:80/news/lnc-therapeutics-raises-65m-to-reinforce-its-rd-in-the-microbiota-field.html